- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01460368
A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects of a Supratherapeutic Dose of LY2409021 in Healthy Subjects
Part A: The purpose of Part A of the study is to look at the electrocardiogram (ECG) effects due to blood sugar changes after a meal compared to when LY2409021 is also given with a meal.
Part B: The purpose of Part B is to evaluate the effect of LY2409021, when given at a dose level much higher than what would normally be given, on the electrical activity of the heart as measured by ECG in relation to placebo and moxifloxacin.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Texas
-
Dallas, Texas, Stany Zjednoczone
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- are overtly healthy males or females, as determined by medical history and physical examination
- female participants: women not of child-bearing potential due to surgical sterilization (hysterectomy alone or at least 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy or tubal ligation) confirmed by medical history, or menopause Women with an intact uterus are deemed postmenopausal if they are >=45 years old, have not taken hormones or oral contraceptives within the last year, had cessation of menses for at least 1 year, or have had 6 to 12 months of amenorrhea with follicle-stimulating hormone levels consistent with postmenopausal state
- have a body mass index (BMI) of 18.5 to 32 kilograms per meter squared (kg/m^2), inclusive, at screening
- have a fasting blood glucose between 54 to 110 milligrams per deciliter (mg/dL) (3.0 to 6.1 millimoles per liter [mmol/L])
- have a clinically normal screening electrocardiogram (ECG) with a measurable QT interval as judged by central reader, which allows accurate measurements of QT interval
- have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
- have venous access sufficient to allow for blood sampling
- are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
- have normal blood pressure and pulse rate (supine) at screening, or with minor deviations judged to be acceptable by the investigator
- have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site
- serum magnesium and potassium equal to or above the lower limit of normal
Exclusion Criteria:
- are currently enrolled in or have completed or discontinued within the last 30 days (from screening) from a clinical trial involving an investigational product; or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
- have known allergies to LY2409021, related compounds or any components of the formulations, or to moxifloxacin
- are persons who have previously received the investigational product in this study, have completed or withdrawn from this study or any other study investigating LY2409021
- personal or family history of long QT syndrome
- family history of sudden unexplained death or cardiac death in a family member under 60 years of age
- personal history of unexplained syncope within the last year
- have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
- regularly use known drugs of abuse and/or show positive findings on urinary drug screening
- show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
- show evidence of hepatitis C and/or positive hepatitis C antibody
- show evidence of hepatitis B and/or positive hepatitis B surface antigen
- are women with a positive pregnancy test or women who are lactating
- intend to use over-the-counter (including mineral supplements and herbal medicine) or prescription medication within 7 days prior to dosing
- have donated blood of more than 500 milliliters (mL) within the last month
- have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females) (1 unit = 12 ounces [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits), or are unwilling to comply with alcohol restrictions during the study (that is, refrain from alcohol consumption from 24 hours prior to dosing until the completion of each treatment period and to consume no more than 2 units of alcohol per day between treatment periods)
- are participants who smoke more than 10 cigarettes per day and/or are unable to abide by the study restrictions for smoking/tobacco use (that is, refrain from smoking for approximately 2 hours prior to each ECG timepoint or for a total of approximately 12 hours)
- are participants who are unable to abide by the study restrictions for caffeine/xanthine use (that is, refrain from consuming caffeine/xanthine containing drinks and foods [such as coffee, tea, cola, and chocolate] on days on which ECGs are performed, and maintain consistent consumption habits on all other days of the study)
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Podstawowa nauka
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Part A: LY2409021
Participants will receive 2 standard meals; one alone without LY2409021, and one along with a single dose of 300 milligrams (mg) LY2409021 administered orally.
Participants enrolled in Part A will not be allowed to participate in Part B.
|
Podawany doustnie
|
Eksperymentalny: Part B: LY2409021
300 milligrams (mg) LY2409021 administered orally as a single dose on Day 1 of the relevant treatment period.
The treatment and washout period was a total of 15 days in length.
|
Podawany doustnie
|
Komparator placebo: Part B: Placebo
Administered orally as a single dose on Day 1 of the relevant treatment period.
The treatment and washout period was a total of 15 days in length.
|
Podawany doustnie
|
Aktywny komparator: Part B: Moxifloxacin
400 milligrams (mg) Moxifloxacin administered orally as a single dose on Day 1 of the relevant treatment period.
The treatment and washout period was a total of 15 days in length.
|
Podawany doustnie
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Part B: Mean Change From Baseline in 12-lead Electrocardiogram (ECG) Corrected QT Intervals (LY2409021)
Ramy czasowe: Baseline, 2, 4, 6, 8, 12, and 24 hours
|
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33.
Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves.
Least Squares (LS) means were calculated using mixed effects model with fixed effects for treatment, time, period, sequence, and the time-by-treatment interaction, random effects for participant, the participant-by-treatment interaction, and participant-by-time interaction.
|
Baseline, 2, 4, 6, 8, 12, and 24 hours
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Part B: Mean Change From Baseline in 12-lead Electrocardiogram (ECG) Corrected QT Intervals (Moxifloxacin)
Ramy czasowe: Baseline, 2 and 4 hours
|
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33.
Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves.
Least Squares (LS) means were calculated using mixed effects model with fixed effects for treatment, time, period, sequence, and the time-by-treatment interaction, random effects for participant, the participant-by-treatment interaction, and participant-by-time interaction.
|
Baseline, 2 and 4 hours
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Zaburzenia metabolizmu glukozy
- Choroby metaboliczne
- Choroby układu hormonalnego
- Cukrzyca
- Cukrzyca typu 2
- Molekularne mechanizmy działania farmakologicznego
- Środki przeciwinfekcyjne
- Inhibitory enzymów
- Środki przeciwnowotworowe
- Inhibitory topoizomerazy II
- Inhibitory topoizomerazy
- Środki przeciwbakteryjne
- Moksyfloksacyna
Inne numery identyfikacyjne badania
- 14149
- I1R-FW-GLBP (Inny identyfikator: Eli Lilly and Company)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Cukrzyca typu 2
-
Leiden University Medical CenterZakończonyGruczolak przysadki | Guz przysadki | Diabetes Insipidus Cranial Type | Dokrewny; NiedobórHolandia
-
Centre Hospitalier Universitaire de LiegeSanofi; Takeda; University of Liege; Orchard Therapeutics; Centre Hospitalier Régional... i inni współpracownicyRekrutacyjnyWrodzony przerost nadnerczy | Hemofilia A | Hemofilia B | Mukopolisacharydoza I | Mukopolisacharydoza II | Mukowiscydoza | Niedobór alfa 1-antytrypsyny | Anemia sierpowata | Anemia Fanconiego | Przewlekła choroba ziarniniakowa | Choroba Wilsona | Ciężka wrodzona neutropenia | Niedobór transkarbamylazy ornityny | Mukopolisacharydoza... i inne warunkiBelgia
-
UK Kidney AssociationRekrutacyjnyZapalenie naczyń | AL Amyloidoza | Stwardnienie guzowate | Choroba Fabry'ego | Cystynuria | Ogniskowe segmentowe stwardnienie kłębuszków nerkowych | Nefropatia IgA | Syndrom Barttera | Czysta aplazja czerwonokrwinkowa | Nefropatia błoniasta | Atypowy zespół hemolityczno-mocznicowy | Autosomalna dominująca policystyczna... i inne warunkiZjednoczone Królestwo
Badania kliniczne na Placebo
-
SamA Pharmaceutical Co., LtdNieznanyOstre zapalenie oskrzeli | Ostra infekcja górnych dróg oddechowychRepublika Korei
-
National Institute on Drug Abuse (NIDA)ZakończonyUżywanie konopi indyjskichStany Zjednoczone
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyZakończonyMężczyźni z cukrzycą typu II (T2DM)Niemcy
-
Heptares Therapeutics LimitedZakończonyFarmakokinetyka | Problemy z bezpieczeństwemZjednoczone Królestwo
-
West Penn Allegheny Health SystemZakończonyAstma | Alergiczny nieżyt nosaStany Zjednoczone
-
Soroka University Medical CenterZakończony
-
Regado Biosciences, Inc.ZakończonyZdrowy ochotnikStany Zjednoczone
-
Longeveron Inc.ZakończonyZespół niedorozwoju lewego sercaStany Zjednoczone
-
ItalfarmacoZakończonyDystrofia mięśniowa BeckeraHolandia, Włochy